Hematologic complications in a patient with Glycine soja polyagglutination following fresh frozen plasma transfusion

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

3
Reader(s)
4
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Related articles

VOLUME 33 , ISSUE 2 (June 2017) > List of articles

Hematologic complications in a patient with Glycine soja polyagglutination following fresh frozen plasma transfusion

Ryan P. Jajosky * / Lloyd O. Cook / Elizabeth Manaloor / James F. Shikle / Roni J. Bollag

Keywords : unclassified polyagglutination, Glycine soja, Staphylococcus aureus, lectin, minor crossmatch, T activation  

Citation Information : Immunohematology. Volume 33, Issue 2, Pages 51-55, DOI: https://doi.org/10.21307/immunohematology-2019-007

License : (Transfer of Copyright)

Published Online: 09-October-2019

ARTICLE

ABSTRACT

Polyagglutination is a rare and underdiagnosed condition, characterized by agglutination of red blood cells (RBCs) with almost all ABO-compatible adult sera. Polyagglutination can occur when a cryptantigen is exposed on RBCs via microbial enzyme activity. Because nearly all adults naturally produce antibodies against cryptantigens, transfusion of plasma can cause unexpected hemolysis and hematologic complications, such as thrombocytopenia and disseminated intravascular coagulation, in patients whose cryptantigens are exposed. We report a case of Glycine soja polyagglutination occurring in a 60-year-old African-American man with disseminated methicillin-resistant Staphylococcus aureus (MRSA) infection. Prior to transfusion, the patient developed severe anemia of unknown etiology. Following transfusion of 3 units of fresh frozen plasma (FFP), his RBC count could not be determined for 24 days because of RBC agglutination in his blood sample. In addition, the FFP transfusion correlated with the rapid development of severe, transfusionrefractory thrombocytopenia and anemia. The perplexed clinical team consulted the blood bank. A direct antiglobulin test demonstrated 1+ mixed-field reactivity with both monoclonal anti-IgG and anti-C3d. Lectin panel testing showed reactivity with only Glycine soja, confirming the condition. Subsequently, plasma components were avoided, and RBC and platelet (PLT) components were washed prior to transfusion. After a 44-day hospitalization involving the transfusion of 22 units of RBCs and 13 units of PLTs, the patient was discharged to a long-term care facility. The patient’s confounding hematologic complications can best be explained by polyagglutination, which developed secondary to the severe MRSA infection. The FFP transfusion likely passively transferred antibodies that bound to the patient’s RBC cryptantigens, leading to RBC agglutination and anemia. The development of severe thrombocytopenia may be related to cryptantigen exposure on the patient’s PLTs. Although difficult to identify, polyagglutination needs to be recognized to appropriately manage hemotherapy. The purpose of this case study is to report hematologic complications following FFP transfusion in a patient with Glycine soja polyagglutination, a rarely described condition.

Content not available PDF Share

FIGURES & TABLES

REFERENCES

1. Horn KD. The classification, recognition and significance of polyagglutination in transfusion medicine. Blood Rev 1999;13:36–44.

2. Beck ML. Red blood cell polyagglutination: clinical aspects. Semin Hematol 2000;37:186–96.

3. Eder AF, Manno CS. Does red-cell T activation matter? Br J Haematol 2001:114:25–30.

4. Rickard KA, Robinson RJ, Worlledge S. Acute acquired haemolytic anaemia associated with polyagglutination. Arch Dis Child 1969;44:102–5.

5. Wang Q, Liu D, Bai Y. T-cryptantigen (TCA) activation in severe pneumonia complicated with multiple organ failure. Transfus Apheresis Sci 2010;43:361–4.

6. Bird T, Stephenson J. Acute haemolytic anaemia associated with polyagglutinability of red cells. J Clin Pathol 1973;26:868–70.

7. Levene C, Sela R, Blat J, et al. Intravascular [correction of intracellular] hemolysis and renal failure in a patient with T polyagglutination. Transfusion 1986;26:243–5.

8. Cochran J, Panzarino V, Maes L, et al. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatric Nephrol 2004;19:317–21.

9. Hopkins C, Yuan S, Lu Q, et al. A severe case of atypical hemolytic uremic syndrome associated with pneumoccal infection and T activation treated successfully with plasma exchange. Transfusion 2008;48:2448–52.

10. Boralessa H, Modi N, Cockburn H, et al. RBC T activation and hemolysis in a neonatal intensive care population: implications for transfusion practice. Transfusion 2002;42:1428–34.

11. Ramasethu J, Luban N. T activation. Br J Haematol 2001;112:259–63.

12. Crookston KP, Reiner AP, Cooper LJN. RBC T activation and hemolysis: implications for pediatric transfusion management. Transfusion 2000;40:801–12.

13. Bird GWG. Lectins in immunohematology. Transfusion Med Rev 1989;3:55–62.

14. Wang LY, Chan YS, Chang FC, et al. Thomsen-Friedenreich activation in infants with necrotizing enterocolitis in Taiwan. Transfusion 2011;51:1972–6.

15. Eversole M, Nonemaker B, Zurek K, et al. Uneventful administration of plasma products in a recipient with T-activated red cells. Transfusion 1986;26:182–5.

16. Fung MK, Grossman BJ, Hillyer CD, et al. AABB technical manual. 18th ed. Bethesda, MD: AABB, 2014.

17. Buskila D, Levene C, Bird GWG. Polyagglutination in hospitalized patients: a prospective study. Vox Sang 1987;52:99–102.

18. Leger R, Lines E, Cunningham K, Garratty G. A new form of polyagglutination related to Cad. Immunohematology 1996;12:69–71.

EXTRA FILES

COMMENTS